Concepedia

Publication | Open Access

Cabozantinib in Progressive Medullary Thyroid Cancer

DOIFull Paper Access

1.2K

Citations

29

References

2013

Year

Rossella Elisei, Martin Schlumberger, Stefan Müller, Patrick Schöffski, Marcia S. Brose, Manisha H. Shah, Lisa Licitra, Barbara Jarząb, Michael C. Kreißl, Bruno Niederle,
Journal of Clinical Oncology

Abstract

Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease. This dose of cabozantinib was associated with significant but manageable toxicity.

References

YearCitations

Page 1